Document is current
Any future updates will be listed below
-
Authors
Herrera, Victoria L. M. https://orcid.org/0000-0001-8991-2134
Bosch, Nicholas A.
Lok, Judith J.
Nguyen, Mai Q.
Lenae, Kaitriona A.
deKay, Joanne T.
Ryzhov, Sergey V.
Seder, David B.
Ruiz-Opazo, Nelson
Walkey, Allan J.
-
Funding
Funding for this research was provided by:
Office of Extramural Research, National Institutes of Health (5U54HL 119145-07)
Office of Extramural Research, National Institutes of Health (1KL2TR001411)
Office of Extramural Research, National Institutes of Health (5U54GM11516-03)
Office of Extramural Research, National Institutes of Health (1UL1TR001430)
- License Information
-
More Information
Article History
Received: 15 January 2023
Accepted: 24 March 2023
First Online: 18 April 2023
Declarations
:
: Procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as most recently amended ( ).At Boston Medical Center (BMC), the protocol study number is H-36744, study title: Humanized anti-DEspR antibody therapy for Acute Lung Injury (ALI/Acute Respiratory Distress Syndrome), and approval by Boston University’s Institutional Review Board on 12–01-2019. At Maine Medical Center (MMC), the protocol study number is 1598969–16, with study title “IT-19 Identification of molecular treatment targets for COVID-19”, and approval by Maine Medical Center’s Institutional Review Board on 5/8/2020. Clinical data and blood sample collections followed IRB approved protocols.
: Not applicable.
: Boston University holds awarded patents on DEspR as novel therapeutic approach for cancer, stroke, COVID-19, NETosis and activated neutrophils. VLMH and NRO are co-inventors in patents filed by Boston University.
